Skip to main content

Congenital Muscular Torticollis

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ability Pharma
Ability PharmaSpain - Cerdanyola
1 program
Perception-Action ApproachN/A1 trial
Active Trials
NCT02907801Terminated5Est. Mar 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ability PharmaPerception-Action Approach

Clinical Trials (1)

Total enrollment: 5 patients across 1 trials

NCT02907801Ability PharmaPerception-Action Approach

Perception-Action Approach Intervention for Infants With Congenital Muscular Torticollis

Start: Jan 2017Est. completion: Mar 20185 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.